Презентация на тему:"Болезнь Альцгеймера" расскажет об этом заболевании, этимологии,клинической картины этого заболевания, также можно просмотреть как прогрессирует "Болезнь Альцгеймера"
Seizures. These are disorders characterized by excessive or oversynchronized discharges of cerebral neurons. Seizures can result from either primary central nervous system dysfunction or an underlying metabolic derangement or systemic disease. This distinction is critical, since therapy must be directed at the underlying disorder as well as at seizure control.
January 23, 2017
The Fifth Annual Health Law Year in P/Review symposium featured leading experts discussing major developments during 2016 and what to watch out for in 2017. The discussion at this day-long event covered hot topics in such areas as health policy under the new administration, regulatory issues in clinical research, law at the end-of-life, patient rights and advocacy, pharmaceutical policy, reproductive health, and public health law.
The Fifth Annual Health Law Year in P/Review was sponsored by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, Harvard Health Publications at Harvard Medical School, Health Affairs, the Hastings Center, the Program On Regulation, Therapeutics, And Law (PORTAL) in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital, and the Center for Bioethics at Harvard Medical School, with support from the Oswald DeN. Cammann Fund.
Learn more on our website: http://petrieflom.law.harvard.edu/events/details/5th-annual-health-law-year-in-p-review
Data You May Like: A Recommender System for Research Data DiscoveryAnusuriya Devaraju
Various data portals been developed to facilitate access to research datasets from different sources. For example, the Data Publisher for Earth & Environmental Science (PANGAEA), the Registry of Research Data Repositories (re3data.org), and the National Geoscience Data Centre (NGDC). Due to data quantity and heterogeneity, finding relevant datasets on these portals may be difficult and tedious. Keyword searches based on specific metadata elements or multi-key indexes may return irrelevant results. Faceted searches may be unsatisfactory and time consuming, especially when facet values are exhaustive. We need a much more intelligent way to complement existing searching mechanisms in order to enhance user experiences of the data portals.
We developed a recommender system that helps users to find the most relevant research datasets on the CSIRO’s Data Access Portal (DAP). The system is based on content-based filtering. We computed the similarity of datasets based on data attributes (e.g., descriptions, fields of research, location, contributors, and provenance) and inference from transaction logs (e.g., the relations among datasets and between queries and datasets). We improved the recommendation quality by assigning weights to data similarities. The weight values are drawn from a survey involving data users. The recommender results for a given dataset are accessible programmatically via a web service. Taking both data attributes and user actions into account, the recommender system will make it easier for researchers to find and reuse data offered through the data portal.
January 23, 2017
The Fifth Annual Health Law Year in P/Review symposium featured leading experts discussing major developments during 2016 and what to watch out for in 2017. The discussion at this day-long event covered hot topics in such areas as health policy under the new administration, regulatory issues in clinical research, law at the end-of-life, patient rights and advocacy, pharmaceutical policy, reproductive health, and public health law.
The Fifth Annual Health Law Year in P/Review was sponsored by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, Harvard Health Publications at Harvard Medical School, Health Affairs, the Hastings Center, the Program On Regulation, Therapeutics, And Law (PORTAL) in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital, and the Center for Bioethics at Harvard Medical School, with support from the Oswald DeN. Cammann Fund.
Learn more on our website: http://petrieflom.law.harvard.edu/events/details/5th-annual-health-law-year-in-p-review
Seizures. These are disorders characterized by excessive or oversynchronized discharges of cerebral neurons. Seizures can result from either primary central nervous system dysfunction or an underlying metabolic derangement or systemic disease. This distinction is critical, since therapy must be directed at the underlying disorder as well as at seizure control.
January 23, 2017
The Fifth Annual Health Law Year in P/Review symposium featured leading experts discussing major developments during 2016 and what to watch out for in 2017. The discussion at this day-long event covered hot topics in such areas as health policy under the new administration, regulatory issues in clinical research, law at the end-of-life, patient rights and advocacy, pharmaceutical policy, reproductive health, and public health law.
The Fifth Annual Health Law Year in P/Review was sponsored by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, Harvard Health Publications at Harvard Medical School, Health Affairs, the Hastings Center, the Program On Regulation, Therapeutics, And Law (PORTAL) in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital, and the Center for Bioethics at Harvard Medical School, with support from the Oswald DeN. Cammann Fund.
Learn more on our website: http://petrieflom.law.harvard.edu/events/details/5th-annual-health-law-year-in-p-review
Data You May Like: A Recommender System for Research Data DiscoveryAnusuriya Devaraju
Various data portals been developed to facilitate access to research datasets from different sources. For example, the Data Publisher for Earth & Environmental Science (PANGAEA), the Registry of Research Data Repositories (re3data.org), and the National Geoscience Data Centre (NGDC). Due to data quantity and heterogeneity, finding relevant datasets on these portals may be difficult and tedious. Keyword searches based on specific metadata elements or multi-key indexes may return irrelevant results. Faceted searches may be unsatisfactory and time consuming, especially when facet values are exhaustive. We need a much more intelligent way to complement existing searching mechanisms in order to enhance user experiences of the data portals.
We developed a recommender system that helps users to find the most relevant research datasets on the CSIRO’s Data Access Portal (DAP). The system is based on content-based filtering. We computed the similarity of datasets based on data attributes (e.g., descriptions, fields of research, location, contributors, and provenance) and inference from transaction logs (e.g., the relations among datasets and between queries and datasets). We improved the recommendation quality by assigning weights to data similarities. The weight values are drawn from a survey involving data users. The recommender results for a given dataset are accessible programmatically via a web service. Taking both data attributes and user actions into account, the recommender system will make it easier for researchers to find and reuse data offered through the data portal.
January 23, 2017
The Fifth Annual Health Law Year in P/Review symposium featured leading experts discussing major developments during 2016 and what to watch out for in 2017. The discussion at this day-long event covered hot topics in such areas as health policy under the new administration, regulatory issues in clinical research, law at the end-of-life, patient rights and advocacy, pharmaceutical policy, reproductive health, and public health law.
The Fifth Annual Health Law Year in P/Review was sponsored by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, Harvard Health Publications at Harvard Medical School, Health Affairs, the Hastings Center, the Program On Regulation, Therapeutics, And Law (PORTAL) in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital, and the Center for Bioethics at Harvard Medical School, with support from the Oswald DeN. Cammann Fund.
Learn more on our website: http://petrieflom.law.harvard.edu/events/details/5th-annual-health-law-year-in-p-review
On May 23, Conifer Health Solutions hosted a lecture at the ACHE Fellows Seminar in San Antonio, TX. The lecture, “Planning for Success with Clinical Integration,” focused on the steps associated with building a clinically integrated network; the power of strategic alignment with partners in the care community; and sustainable governance and incentive structures for the clinically integrated network.
January 23, 2017
The Fifth Annual Health Law Year in P/Review symposium featured leading experts discussing major developments during 2016 and what to watch out for in 2017. The discussion at this day-long event covered hot topics in such areas as health policy under the new administration, regulatory issues in clinical research, law at the end-of-life, patient rights and advocacy, pharmaceutical policy, reproductive health, and public health law.
The Fifth Annual Health Law Year in P/Review was sponsored by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, Harvard Health Publications at Harvard Medical School, Health Affairs, the Hastings Center, the Program On Regulation, Therapeutics, And Law (PORTAL) in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital, and the Center for Bioethics at Harvard Medical School, with support from the Oswald DeN. Cammann Fund.
Learn more on our website: http://petrieflom.law.harvard.edu/events/details/5th-annual-health-law-year-in-p-review
2. Определение
Болезнь Альцгеймера (также сенильная
деменция альцгеймеровского типа) —
наиболее распространённая форма
деменции, нейродегенеративное
заболевание, впервые описанное в 1906
году немецким психиатром Алоисом
Альцгеймером. Как правило, она
обнаруживается у людей старше 65 лет, но
существует и ранняя болезнь
Альцгеймера — редкая форма
заболевания.
3. Этиология
Несмотря на огромное количество исследований о
болезни Альцгеймера в последние десятилетия, причина
большинства случаев заболевания остаётся неизвестной.
В настоящее время рассматривается более десяти
различных теорий, объясняющих причину возникновения
болезни Альцгеймера.
Считается, что заболевание гетерогенно по своему
происхождению: в одних случаях оно носит
наследственный характер, в других – нет.
При раннем начале болезни до 65 лет основной причиной
большинства случаев является наследственность.
Семейные формы с ранним началом составляют лишь 10%
из общего количества больных. Недавние исследования в
области генетики болезни Альцгеймера позволили
идентифицировать три гена, которые отвечают за
развитие семейных, наследственно-обусловленных форм
заболевания. Наличие данных генов означает почти 100%
риск развития болезни Альцгеймера.
Несмотря на достижения молекулярной генетики,
которые доказали генетическую природу значительной
части семейных случаев БА, тем не менее остаётся не
ясным значение генетических факторов в возникновении
более 80% всех случаев болезни Альцгеймера
4. Клиническая картина
По данным клинико- морфологических сопоставлений, дегенеративный процесс
при болезни Альцгеймера (рис. 35-1) начинается приблизительно за 10-15 лет
до появления первых клинических симптомов (латентная, или доклиническая ,
стадия). Затем исподволь формируются нарушения памяти (так называемая
доброкачественная старческая забывчивость). Этот этап характеризуется
сохранной критикой к своему состоянию и относительной сохранностью других
когнитивных функций (кроме памяти).
Основные клинические характеристики болезни Альцгеймера:
Дебют Развернутые стадии
Когнитивные функции Нарушения памяти на
недавние события.
Отдалённая память
сохранна
Выраженные
нарушения памяти,
апрактоагностический
синдром, нарушения
речи
Поведение Тревожно-
депрессивные
расстройства
Подозрительность,
агрессивность, бред
Неврологический
статус
Нет нарушений. Редко
гипокинезия,
повышение тонуса по
пластическому типу
Нет нарушений. Лишь
в финале нарушения
походки и
мочеиспускания
МРТ головы Атрофия гиппокампа Атрофия гиппокампа
5. Критерии
степени
тяжести
заболевания
Лягкая Средняя Тяжелая
• Пофессиона
льная
деятельност
ь и
социальная
активность
отчетливо
ограничены;
• трудности
при
самостоятел
ьном
проживании;
• активность в
повседневной
жизни
нарушена;
• необходимы
постоянное
обслуживание
и уход;
• Coхроняется
способность
жить
самостоятел
ьно,
умственные
способности
не
затронуты
• необходим
определенн
ый контроль
• неспособность
соблюдать
минимальную
личную
гигиену;
Степень тяжести